Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):e79-82. doi: 10.1097/QAI.0000000000000873.

Abstract

Supplemental Digital Content is Available in the Text.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / virology*
  • CCR5 Receptor Antagonists / pharmacology*
  • Cyclohexanes / pharmacology*
  • Drug Resistance, Viral*
  • HIV-1 / drug effects*
  • Humans
  • Maraviroc
  • Mutation
  • Triazoles / pharmacology*
  • env Gene Products, Human Immunodeficiency Virus / genetics
  • env Gene Products, Human Immunodeficiency Virus / metabolism

Substances

  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • Triazoles
  • env Gene Products, Human Immunodeficiency Virus
  • Maraviroc